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doi:10.1016/j.ejvs.2011.01.021Abstract Objective: To compare 1-year potencies’ of heparin-bonded PTFE [(Hb-PTFE)
(Propaten)] grafts with those of ordinary polytetraflouroethylene (PTFE) grafts in a blinded,
randomised, clinically controlled, multi-centre study.
Materials and methods: Eleven Scandinavian centres enrolled 569 patients with chronic func-
tional or critical lower limb ischaemia who were scheduled to undergo femoroefemoral bypass
or femoroepoplitaeal bypass. The patients were randomised 1:1 stratified by centre. Patency
was assessed by duplex ultrasound scanning. A total of 546 patients (96%) completed the study
with adequate follow-up.XIV annual ESVS meeting in Amsterdam, 18 September 2010.
9272447; fax: þ45 8786 4718.
rg.rm.dk (J.S. Lindholt).
lsevier Ltd on behalf of European Society for Vascular Surgery.
The Scandinavian Propaten Trial 669Results: Perioperative bleeding was, on average, 370 ml with PTFE grafts and 399 ml with
Heparin-bonded PTFE grafts (p Z 0.32).
Overall, primary patency after 1 year was 86.4% for Hb-PTFE grafts and 79.9% for PTFE grafts
(OR Z 0.627, 95% CI: 0.398; 0.989, p Z 0.043). Secondary patency was 88% in Hb-PTFE grafts
and 81% in PTFE grafts (OR Z 0.569 (0.353; 0.917, p Z 0.020)).
Subgroup analyses revealed that significant reduction in risk (50%) was observed when Hb-
PTFE was used for femoroepoplitaeal bypass (OR Z 0.515 (0.281; 0.944, p Z 0.030)), and
a significant reduction in risk (50%) was observed with Hb-PTFE in cases with critical ischaemia
(OR Z 0.490 (0.249; 0.962, p Z 0.036)).
Conclusion: The Hb-PTFE graft significantly reduced the overall risk of primary graft failure by
37%. Risk reduction was 50% in femoroepoplitaeal bypass cases and in cases with critical
ischaemia.
ª 2011 Published by Elsevier Ltd on behalf of European Society for Vascular Surgery.Neointimal hyperplasia formation at the anastomoses of
bypass surgery is a well-known complication that threatens
the patency of the reconstruction. An experimental study
from 1988 showed that prolonged heparin injections
resulted in reduced neointimal hyperplasia.1 The benefit of
this inhibition was confirmed by clinical trials, including
a randomised study of 200 femoroepoplitaeal bypasses;
half of the patients enrolled in the study underwent 3
months of treatment with subcutaneous, low molecular
heparin, and the other half received low-dose aspirin and
dipyridamole.2 After 12 months, the patencies were 87%
and 72%, respectively (p Z 0.02). However, the results
were never implemented into clinical practice.
The results urged the execution of experimental studies
to create artificial prostheses with heparin bound to the
luminal surface. The benefits of heparin were first
demonstrated with Dacron. A randomised multi-centre
study of 180 femoroepoplitaeal bypasses randomised
patients 1:1 to heparin-bound Dacron grafts or polytetra-
fluoroethylene (PTFE) grafts; the first-year patency values
were 75% and 58%, respectively (pZ 0.037).3 Despite these
findings, there were no significant changes in clinical
practice, perhaps due to a preference for PTFE.
Since 2002, PTFE vascular prostheses with heparin-
bound luminal surfaces have been commercially available.
A small prospective observational study suggested similar
effects for long-term subcutaneous heparin application and
heparin-bound Dacron prostheses.4 However, no Level I
evidence of any benefit exists. Consequently, the aim of
this study was to compare the primary patency at 1 year of
heparin-bound PTFE (Propaten) versus pure PTFE grafts in
a robust, randomised, blinded, clinically controlled, multi-
centre study.
Materials and Methods
Power calculations
The researchers agreed to conduct the trial with
a substantial power of 90% to minimise the risk of failing to
detect a relevant difference in patency. Significance level
was set at 5%. It seemed realistic and appropriate to expect
a difference of 17% in primary patency for femo-
roepoplitaeal (femepop) bypasses, as reported by Devine
and McCollum,3 as well as a corresponding relative risk (RR)
of femoroefemoral cross-overs (femefem) bypasses usingthe results from the Scandinavian FLUX-study as a refer-
ence for the crude PTFE graft.5 The ratio between
femefems and femepops was expected to be 1:1 based on
data from the Danish Vascular Registry (Karbasen). If
patients were randomised 1:1, then the 362 participants
would be expected to achieve 80% power, and 484 would be
expected to achieve 90% power.
Inclusion and exclusion criteria
From 2006 to 2009, patients with intermittent claudication
or chronically critical ischaemia evaluated at 11 Scandina-
vian vascular centres were considered for inclusion in the
trial. Inclusion criteria were clinical indication for
femefem cross-over or femepop bypass above or below the
knee with an artificial graft, as determined by angiography.
Acute patients and patients not likely to attend follow-up,
as well as those with heparin allergies, were excluded.
Randomisation
Stratified randomisation by each centre was performed (1:1)
by the principal investigator using Epi-Info-6. In connection
with the offer of surgery, the patient was informed of the
study both verbally and in writing and then asked to
participate. Written consent was obtained from each
participant. Identification number and date of recruitment
were recorded on the enrolment list, and the corresponding
numbered envelope was attached to the medical record.
The randomisation envelope was opened in the operating
room by assisting personnel. The majority of the centres
performed this type of randomisation. However, a few
centres could not organise this, thereby causing some
technical errors (Fig. 1). In all cases, the surgeonwas blinded
with regard to the group assignment of each patient.
However, experienced surgeons were able to distinguish
between the two types of grafts due to slightly different blue
markings on the two types of PTFE grafts. Follow-up
assessments were performed in a double-blinded manner so
that information on graft material was not available when
clinical follow-up was performed. Throughout the trial, the
blinding codes were located at the administration office of
Viborg Hospital. These codes were broken by the principal
investigator only after 1 complete year of follow-up had
been reported by all participating centres, and the primary
analyses had been done.
569 Randomised
555 Operated
546 1 year 
follow up
Primary patent: 454
Secondary patent:  462
Primary not patent: 92
Secondary not patent : 84
Technical failures: 5
Use of wrong graft: 5
Change of indication: 4
Death before follow up: 4
Lost for follow up: 7
Figure 1 Flow chart.
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Age, gender, diabetic status, weight, height, total choles-
terol, S-creatinine, indication for surgery, preoperative and
post-operative discharge ankle blood pressure index (ABI),
type of intended bypass, anti-platelets and statins given at
discharge were recorded as baseline variables.
Participants
A total of 569 patients were randomised. Of these, 555
underwent the planned procedure. Exclusions were
primarily due to technical errors, such as a missing enve-
lope or use of the wrong graft. Of those who underwent the
scheduled procedure, 11 of the 555 patients operated were
lost for follow-up. These were equally divided between the
groups. The follow-up time in the control group and the
intervention group was 9.75  3.79 versus 10.30  3.35
months, respectively. Consequently, 546 had follow-up
data for the assessment of 1-year primary patency, which
were equally distributed between crude PTFE (n Z 272)
and heparin-bonded PTFE (nZ 274). Drop-outs were mainly
due to loss of follow-up, although a few deaths occurred
before follow-up (Fig. 1).
Follow-up variables
To assess whether the graft was open or closed, we evalu-
ated peripheral pulse and measured systolic ankle/arm
blood pressure at each outpatient’s follow-up examination
up to 12 months postoperatively. Occlusion was suspected
when a previously palpated pulse was diminished and/or
a significant decrease (>15%) was observed between the
ABI value at follow-up versus the ABI value measured in the
immediate post-operative period. Confirmation of occlu-
sion was done via duplex scanning of the graft or angiog-
raphy. The date of occlusion was recorded. At 1 year post-
operation, all non-occluded grafts underwent duplex
scanning for the valid assessment of patency and for
purposes of revealing any ‘silent’occlusions.
The type and date of any additional interventions to
correct stenoses or reopen the reconstruction were also
recorded.
Primary and secondary effect variables
Primary patency was considered as the primary effect vari-
able. The secondary effect variable was secondary patency.Statistical analysis
To investigate potential failed randomisation, dichotomous
and continuous baseline variables were compared between
the two study arms by the chi-squared test and Student’s t-
test, respectively.
Primary and secondary first-year patencies were
compared between the two groups using logistic regression
analysis with and without an adjustment for bypass type
and critical ischaemia. These analyses were pre-specified
to be by Cox-regression analyses, but were post-hoc
changed to logistic regression analysis due to the observa-
tion of a substantial number of silent occlusions. Similarly,
subgroup analyses were performed for primary patency
with regard to the type of bypass and critical ischaemia.
These were also performed post hoc due to requests from
editors and reviewers.
The analyses were performed by the ‘intention-to-treat
principle’ excluding those after randomisation who did not
undergo the planned bypass but including early (technical)
failures and prosthetic infections.
Ethical aspects
The heparinised graft is approved for commercial use, and
there is no clinical suspicion that it increases perioperative
bleeding or patient risk. Patients were informed verbally
and in writing of the study parameters, and informed
consent was obtained from each patient before implanta-
tion. The trial was approved by all of the involved Scientific
Ethical Committees and data protection authorities in
Denmark, Norway and Sweden.
Results
As mentioned, 546 patients had sufficient follow-up data.
Among these patients, the mean age was 65.6  5.8 years;
53%weremale; 54%were current smokers; 15% haddiabetes;
mean ABIwas 0.43 0.19; 36% had critical ischaemia and 54%
had a femefem cross-over bypass. No significant differences
between groups were noted for any of these baseline vari-
ables (Table 1). No differenceswere noted in operation time,
preoperative bleeding or primary admission time.
Primary patency
In all, 454 grafts were primarily patent during the first year
(Fig. 1). Of the 274 implanted crude PTFE grafts, 219
(79.9%) were primarily patent after 1 year, as compared to
235 out of 272 (86.6%) implanted heparin-bonded PTFE
grafts (odds ratio (OR) Z 0.627, 95% CI: 0.398; 0.989,
p Z 0.043, Fig. 2). The 37% lower risk in patients with
heparin-bonded PTFE grafts remained unchanged after
adjustment for the type of bypass, but significance was lost
(adjusted OR Z 0.629; 95% CI: 0.393; 1.001, p Z 0.051).
Femepop bypasses were significantly associated with
a threefold higher risk of losing primary patency (adjusted
OR: 2.994; 95% CI: 1.860; 4.1819, p < 0.001), and critical
ischaemia was associated with more than twice the risk of
losing primary patency (adjusted OR Z 2.260; 95% CI:
1.416; 3.607).
Table 1 Baseline characteristics classified according to type of graft.
Graft P-value Total
PTFE Heparin-bonded PTFE
Dichotomous variables
Male 148 (54.0%) 140 (51.5%) 0.552 288 (52.7%)
Smokers 147 (54.2%) 144 (53.3%) 0.832 291 (53.8%)
Diabetes Mellitus 39 (14.6%) 39 (15.0%) 0.398 68 (14.8%)
Critical ischaemia 98 (36.5%) 100 (36.0%) 0.910 198 (36.3%)
Femefem bypass 148 (51.2%) 160 (56.7%) 0.372 308 (54.1%)
No statins at discharge 43 (15.0%) 31 (11.0%) 0.179 74 (13.0%)
No anti-platelets at discharge 4 (1.39%) 12 (4.25%) 0.089 16 (1.75%)
Continuous variables
Age 65.7 (5.78) 65.4 (5.97) 0.961 65.6 (5.84)
Body mass index 25.2 (4.79) 25.3 (4.79) 0.707 25.2 (0.21)
P-total cholesterol 4.50 (1.05) 4.44 (1.03) 0.558 4.46 (1.04)
S-creatinine 89.4 (48.7) 86.4 (43.5) 0.554 87.9 (46.2)
Preoperative ankle blood
pressure index
0.43 (0.17) 0.44 (0.19) 0.571 0.43 (0.19)
The Scandinavian Propaten Trial 671Secondary patency
In all, 462 (84.4%) grafts were secondarily patent after the
first year. Of the 274 implanted crude PTFE grafts, 222
(81%) remained secondarily patent, whereas 240 out of 272
(88%) implanted heparin-bonded PTFE grafts remained
secondarily patent (RR Z 0.60; 95% CI: 0.39; 0.93,
p Z 0.024). The significant 40% reduction in risk for
heparin-bonded PTFE grafts remained unchanged after
adjustment for type of bypass and critical ischaemia
(adjusted OR Z 0.565; 95% CI: 0.346; 0.923, p Z 0.023).
Femepop bypasses and critical ischaemia were bothFigure 2 One-year primary patency of Heparin-bonded PTFE and cassociated with over a twofold higher risk of losing
secondary patency (adjusted OR Z 2.650; 95% CI: 1.625;
4.322, p < 0.001; adjusted OR: 2.506 95% CI: 1.545; 4.066,
p < 0.001, respectively).Subgroup analyses
In all, 275 of 307 (89.6%) femefem cross-over bypasses
were primarily patent throughout the first year; of the 147
implanted crude PTFE grafts, 131 (89.1%) remained
primarily patent as compared to 144 out of 160 (90.0%)rude PTFE grafts incl. silent occlusions discovered after one year.
672 J.S. Lindholt et al.implanted heparin-bonded PTFE grafts (OR Z 0.910; 95%
CI: 0.437; 1.896, p Z 0.800).
In all, 173 of 232 (74.6%) femepop bypasses were
primarily patent throughout the first year; of the 107
implanted heparin-bonded PTFE grafts, 86 (80.4%)
remained primarily patent as compared to 87 out of 125
(69.6%) implanted crude PTFE grafts (OR Z 0.515; 95% CI:
0.281; 0.944, p Z 0.030).
In all, 151 of 198 (76.3%) bypasses implanted for chroni-
cally critical ischaemia were primarily patent after the first
year; of the 100 implanted crude PTFE grafts, 70 (70%)
remained primarily patent as compared to 81 out of 98
(82.7%) implanted heparin-bonded PTFE grafts (ORZ 0.490;
95% CI: 0.249; 0.962, pZ 0.036). This difference remained
significant after adjustment for type of bypass (ORZ 0.47;
95% CI: 0.26; 0.86).
The subgroup results are further described with details
in Table 2.
Discussion
In this relatively large, randomised, clinically controlled
trial, heparin-bonded PTFE grafts significantly decreased
the relative risk of losing primary and secondary patency by
36% and 40%, respectively. The benefit was most marked in
cases reconstructed for critical ischaemia and in femepop
bypasses, in which the risk of losing primary patency was
halved. The aim of this trial was to test whether there are
any differences in the patencies of the two types of grafts,
not which graft to choose in a specific clinical situation. The
randomised design secures, by principle, equal distribution
of the heterogeneous populations between the two arms.
However, retrospectively, it was debatable that we did not
stratify the randomisation concerning these very different
populations. Supplemental analyses adjusting for these
variations were performed without changing the results,
indicating that randomisation was successful. However,
there was loss of significance concerning overall primary
patency, which must be interpreted as a consequence of
the power for such analysis. In addition, the results of
subgroup analyses are given due to clinical relevance; againTable 2 Subgroup analyses concerning the type of bypass in g
critical lower limb ischaemia or intermittent claudication.
Primary patent N
Femefem cross over bypasses
All Crude PTFE 131 147
Propaten 144 160
Claudicants Crude PTFE 85 88
Propaten 98 106
Critical ischaemia Crude PTFE 46 59
Propaten 46 54
Femepop bypasses
All Crude PTFE 87 126
Propaten 91 112
Claudicants Crude PTFE 64 86
Propaten 56 68
Critical ischaemia Crude PTFE 23 40
Propaten 35 44with the knowledge that power is lost and therefore
increasing the risk of Type II errors. However, due to the
controversial indication for bypass surgery in patients with
intermittent claudication, we did this subgroup analysis in
order to make the results generalisable to centres only
doing bypass surgery for critical ischaemia. In addition, the
subgroup analyses concerning type of bypass were per-
formed due to a substantial expected interest. However, it
must be emphasised that the trial was not powered for this,
and the results must be interpreted with caution.
In spite of being a sufficiently powered, multi-centre
randomised trial and thus providing the highest level of
evidence, potential bias ought to be identified and dis-
cussed as in any other study.
Selection bias may have weakened the external validity
and generalisability of the results. Unfortunately, the
structured information on who accepted the study offer
and who did not was not obtained. However, by extracting
data from the Danish vascular registry concerning femefem
cross-overs and femepops, we calculated that the propor-
tion of patients recruited was about 60%. The Danish
Centres provided information for 85% of the cases. Conse-
quently, no severe selection bias is suspected.
Information bias concerning patency was present to some
degree because several occlusions were first diagnosed at
the mandatory one-year ultrasound-based follow-up
appointment. This independent, and thus non-funded trial,
did not have the resources for regular duplex surveillance
every 3 months. The lack of regular duplex surveillance
caused a potentially substantial information bias, as the
magnitude of the silent occlusions discovered at the
mandatory 1-year duplex scanning was surprisingly high. The
use of survival analysis obviously causes a bias towards the
null-hypothesis. Consequently, the KaplaneMeier Curve
(Fig. 2) and survival analyses include this bias. As a conse-
quence, the first year risk estimation was used with and
without adjustment for critical ischaemia and type of
bypass. This seems acceptable due to the very high propor-
tion of patients having sufficient 1-year follow-up data.
Nevertheless, this information bias challenges the
reported benefit of Propaten.eneral and further subgrouped according to present chronic
Primary patency Odds ratio P-value
89 (84e93)%
90 (84e94)% 0.910 (0.437; 1.896) 0.800
97 (91e99)%
92 (86e96)% 2.312 (0.595; 8.997) 0.215
78 (66e87)%
85 (73e93)% 0.615 (0.233; 1.625) 0.327
69 (61e77)%
81 (73e88)% 0.515 (0.281; 0.944) 0.030
74 (64e83)%
82 (72e90)% 0.623 (0.283; 1.373) 0.238
58 (42e72)%
80 (66e90)% 0.348 (0.133; 0.912) 0.032
The Scandinavian Propaten Trial 673Although randomisation was performed in order to avoid
known and unknown confounders, any randomised trial
poses the risk of being confounded by unsuccessful ran-
domisation. In this trial, there was no indication that the
randomisation had failed to distribute confounders equally
across the two arms (Table 1). However, looking back, the
lack of stratified randomisation concerning type of bypass
must be admitted to be suboptimal. Consequently, logistic
regression analyses were performed univariately and
adjusted for the type of bypass. This adjustment did not
change the significance of results, and thus, confounding
due to this weakness seems to absent.
This trial is the first randomised trial testing the end-
bonding of heparin to the luminal PTFE surface in the
Propaten graft. Whether the results can be generalised to
other heparin-bonded PTFE grafts may be questionable, as
the manufacturers claim it to be more bioactive than other
heparin-bonded PTFE grafts due to the end-bonding of
heparin, while other techniques also causes side-bonding
of heparin, which could impair the bioactive part of
heparin, but published data confirming this is not avail-
able. Another heparin-bonded PTFE graft, the Jotec
graft, has been tested in a large multi-centre randomised
trial in Germany, but the study failed to show overall
significance and has not yet been published.6 Nonetheless,
the PTFE graft was significantly associated with better
patencies concerning femepops above the knee. Taking
these two trials into consideration, the authors strongly
suggest that heparin-bonding improves the patency of
PTFE grafts.
The present trial enrolled nearly 100 cases more than
initially required by power calculations. Nonetheless, the
overall results were not very robust. In addition, the long-
term benefit of the Propaten graft may or may not depend
upon the permanent presence of heparin on the grafts. In
a canine model,7 heparin activity was unchanged after 3
months, but in a sheep model, the bioreactivity of heparin
was similar in crude PTFE and Propaten grafts after 6
months.8 Consequently, the present 1 year results may be
the best that are achievable with this graft, and it is
a major limitation of the study, that follow-up does not
extend longer. The heparin in the Dacron-bonded grafts
disappears after 3 months, but the benefit reported by
Devine and McCollum sustained for at least 5 years.3 Only
time can tell us whether this is also the case for Propaten
grafts. As such, a longer follow-up is needed and is
currently planned for early 2011.Acknowledgements
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